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Abstract
Background: This study aimed to evaluate the patient-reported outcome (PRO) content of ovarian cancer randomised-
controlled trial (RCT) publications, describe PRO compliance, and explore potential relationships among these and
completeness of PRO protocol content.
Methods: Publications of Phase III ovarian cancer RCTs with PRO endpoints were identified by Medline and Cochrane
systematic search: January 2000 to February 2016. Two reviewers determined the number of Consolidated Standards of
Reporting Trials (CONSORT)-PRO Extension items addressed in publications. Compliance rates (defined as the proportion of
participants included in the principal PRO analysis, of those from whom PRO assessments were expected) were extracted.
The relationship between CONSORT-PRO score and compliance rates was explored using scatter plots. Additionally
CONSORT-PRO score and PRO compliance rates respectively were compared with corresponding PRO protocol scores
obtained from a previous study.
Results: Thirty-six eligible RCTs (n = 33 with secondary PRO endpoint) were identified and analysed. The average number of
CONSORT-PRO items addressed in publications was 6.7 (48%; Range 0–13.5/14). Three RCTs did not report PRO results; in 1
case due to poor compliance. Some compliance information was reported in 26 RCTs, but was considered complete for only
10 (28%) RCTs. Compliance rates were poor overall, ranging from 59 to 83%; therefore missing PRO data from 17 to 41% of
participants in these trials could have been avoided.
Of the 26 (73%) RCTs for which PRO protocol completeness scores were available, 6 RCTs reported complete compliance
information and the 3 of these RCTs with highest PRO compliance had highest protocol checklist scores.
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Conclusions: Few RCTs reported PRO compliance information in a manner enabling assessment of the generalisability of PRO
results. This information is particularly important in RCTs of advanced ovarian cancer because it is important to be able to
determine if missing data was due to worsening illness compared to methodological issues. Poor compliance appeared related
to poor PRO protocol content, and in one case prevented PRO results from being reported, highlighting the need to address
compliance strategies in the protocol. Adhering to protocol and CONSORT-PRO reporting guidance should improve PRO
implementation and reporting respectively in ovarian cancer RCTs and allow results to meaningfully inform clinical practice.
Keywords: Quality of life, Patient-reported outcomes, Missing data, Reporting, Ovarian neoplasms
Background
Patient-reported outcomes (PROs), including health-related
quality of life (HRQOL), assessed in cancer randomised
controlled trials (RCTs) provide valuable information on the
impact of treatment from the patient’s perspective [1, 2].
PRO data are increasingly being used to inform clinical prac-
tice guidelines, policy decisions and therapeutic labelling,
with growing support by professional oncology societies,
including European Medical Association (EMA) [3], Ameri-
can Society of Clinical Oncology (ASCO) [4], and European
Society for Medical Oncology (ESMO) [5] to incorporate
PROs in the comprehensive assessment of clinical benefit.
PROs have long been included as secondary endpoints in
ovarian cancer RCTs [6], as treatment is often associated
with significant adverse effects, particularly in patients with
platinum resistant ovarian cancer with poor performance
status and high symptom burden [7]. In patients with
symptomatic recurrent ovarian cancer, chemotherapy can
also palliate symptoms [7]. ESMO recommends that the
primary endpoint of treatment for these patients should be
symptom control and HRQOL [8]. The importance of
evaluating PROs in ovarian cancer RCTs has also been
highlighted by the 3rd [9] and 4th [10, 11] Ovarian Cancer
Consensus meetings and the Food and Drug Administra-
tion (FDA) 2006 Ovarian Cancer Endpoints Workshop
[12]. Yet shortcomings in PRO trial design, methodology
and reporting may limit the interpretation of PRO data and
its potential to inform patient-centred care [13].
A comprehensive RCT protocol with well-considered
PRO hypotheses is essential to communicate the ration-
ale and methods for high-quality PRO data collection. It
is therefore concerning that recent evidence indicates
trial staff perceive PRO data collection guidance to be
inadequate [14]. Insufficient PRO data collection guid-
ance may lead to inconsistent procedures [15], missing
PRO data [16] and potentially misinterpretation of PRO
findings if the RCT publication does not clearly discuss
the associated potential for bias.
Adding to the complexity of PRO interpretation in
oncology is missing data, which may be unavoidable if
related to disease progression or death; in such cases miss-
ing data is considered to be “informative” of poor health
status [17]. However participants who are alive and still
enrolled in the trial may also have missing PRO data,
potentially due to trial staff ‘gate-keeping’ (deciding that
participants are too unwell or that participants should not
complete a questionnaire), administrative errors or partici-
pant refusal, which may be avoidable in many cases by the
provision of high-quality trial guidance or staff training in
the trial protocol [16, 18]. In any case, reasons for missing
data should inform appropriate selection of analysis
methods and accurate data interpretation [16, 17]. Like-
wise this information should be reported to assist readers’
interpretation of findings by differentiating between the
participants who complete PRO assessments as a propor-
tion of the full sample (intention-to-treat population) as
opposed to “PRO assessment compliance”, or the propor-
tion who complete scheduled PRO assessments of those
from whom PRO assessments are expected (participants
still enrolled on the trial) [19]. The latter is considered an
indicator of the efficacy of design and methodological
strategies in preventing avoidable missing data for the
purpose of this study because by definition it acknowl-
edges that PRO assessments cannot be expected from de-
ceased or withdrawn participants.
Another challenge for the uptake of PRO evidence from
RCTs is poor PRO reporting according to CONSORT
(CONsolidated Standards for Reporting) reporting stan-
dards [20–22]. Poor reporting arguably limits the extent
to which PRO data can inform clinical practice. To our
knowledge, no studies to date have explored associations
among PRO protocol content, compliance and reporting.
For any RCT, both the protocol and resultant publica-
tion should clearly articulate PRO hypotheses, endpoints,
methodology and analyses. This is reflected in overlapping
content of the CONSORT-PRO [20] and PRO-specific
guidance for protocols currently in development: SPIRIT-
PRO extension (Standardised Protocol Items for Rando-
mised Trials) [23, 24]. Given the parallels in desirable
content of RCT publications and protocols, we sought to
study links between protocol and publication content.
In our earlier study [25], we established that the PRO
content of 26 ovarian cancer RCT protocols was often sub-
optimal when assessed against a checklist of recommended
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items. On average, protocols addressed less than 1/3 of rec-
ommended PRO items, with most trials offering only basic
information, such as the PRO assessment schedule and
questionnaires used [25]. PRO-specific quality assurance
procedures were generally lacking, as were procedures for
explaining the purpose of PRO assessments to participants,
following up missed assessments and handling missing data
in the analysis [25]; all of which have been identified as im-
portant for minimising the problem of missing PRO data
[16] and for overall protocol completeness [24] suggesting a
potential relationship between PRO content of trial proto-
cols and PRO compliance.
The aims of this study were to describe the quality of
reporting of PROs in ovarian cancer RCTs based on the
CONSORT-PRO Extension; describe PRO compliance
rates and the reporting of PRO compliance. We also
aimed to explore the relationship between CONSORT-
PRO reporting score and other key variables which we
thought may influence reporting, including whether
there was a significant difference in the primary trial
endpoint or the PRO endpoint, compliance rates and
year of publication. We also explored whether the PRO
content of the ovarian cancer RCT protocols reviewed
previously [25] had an impact on: 1) the overall standard
of PRO reporting according to the CONSORT-PRO, and
2) PRO compliance. We hypothesised that RCTs with
more complete PRO protocol content would have more
complete reporting and higher PRO compliance rates.
Methods
Identification of RCTs
Our search and selection strategy were published previ-
ously [25] and summarised in Fig. 1. Briefly, 36 phase III
biomedical ovarian cancer RCTs published between
January 2000 and February 2016 were identified by a sys-
tematic search of Medline and Cochrane Clinical Trials
Fig. 1 Flow diagram of RCT selection
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databases, searching reference lists of eligible RCTs and by
consulting the Gynaecologic Cancer Inter-Group (GCIG)
Symptom Benefit Working Group (SBWG).
RCT protocol scoring
We sought the RCT protocol for all 36 RCTs for evalu-
ation in this study by searching online or by contacting
the corresponding author of the trial publication. Proto-
col authors did not have access to the PRO protocol
checklist, which minimised the risk of them augmenting
their protocols prior to our evaluation.
Two authors (RMB, PK) independently reviewed PRO
content of each protocol obtained (n = 26, Fig. 1) against
a checklist of 58 recommended items (Additional file 1:
Appendix 1a) to minimise bias [25]. A total PRO proto-
col checklist total score (%) was calculated for each
protocol, considering only the checklist items directly ap-
plicable to each RCT. Scoring discrepancies were resolved
upon discussion with a third author (MK, MF or MC).
RCT publications: CONSORT-PRO scoring and compliance
data extraction
Two authors (RMB, PK) independently assessed PRO
content of all eligible RCT publications (n = 36) against
the CONSORT-PRO checklist adapted for review pur-
poses (scoring described in Additional file 1: Appendix
1b), awarding points to each checklist item addressed
and combining into an overall total score (maximum
14). If the RCT was reported across multiple publica-
tions, we considered all publications together and gave a
single score for the RCT.
We defined PRO compliance rate as the proportion of
participants included in the principal PRO analysis, of
those from whom PRO assessments were expected per
protocol (i.e. still on study, still alive) [19]. This level of
reporting was considered necessary to minimise risk of
bias caused by missing PRO data [16] and is also
required by CONSORT-PRO [20]. Two authors (RMB,
PK) extracted PRO compliance information:
1) The actual PRO compliance rate at the principal
time-point of PRO analysis was extracted from pub-
lications, or calculated where this was possible based
on the information reported in the publication.
2) Reporting of compliance was then classified at one of
three possible levels: ‘adequate’ if the RCT reported
compliance information according to our definition
[19] or provided sufficient information for us to
calculate this; ‘incomplete’ if the number of
participants included in PRO analyses or the number
of questionnaires completed at each time-point was
reported but not the number expected (therefore it
was unclear from these publications how many PRO
assessments were missing from analyses due to death
or worsening illness as opposed to ‘avoidable’ rea-
sons). RCTs that failed to report any of this informa-
tion were classified as having reported ‘no
compliance information’. Our grading of compliance
reporting did not consider the actual rate of compli-
ance, therefore it was possible for a trial with a poor
PRO compliance rate to have ‘adequate’ compliance
reporting. Discrepancies were resolved upon discus-
sion (with MK or MC).
Analyses
Relationships among CONSORT-PRO score, the PRO
protocol checklist total score (in the subgroup of 26
RCTs with a protocol), and year of main RCT publica-
tion were examined using scatterplots. Dot plots com-
pared total CONSORT-PRO scores for RCTs that
reported (versus did not report) a significant difference
in either the primary or PRO endpoints.
The potential relationship between PRO compliance
rates at the principal time-point of PRO analysis and
PRO protocol checklist total scores was assessed with a
scatter plot.
The potential relationship between reporting any com-
pliance information (yes vs no) and PRO protocol check-
list total score was assessed with dot plots. RCTs with
‘adequate’ and ‘incomplete’ reporting of compliance were
pooled (these RCTs made an attempt at reporting com-
pliance) and compared against RCTs reporting ‘no com-
pliance information’.
If any of these visual displays suggested an apparent
relationship, an exploratory independent t-test was con-
ducted. All plots and analyses were conducted using
SPSS Version 22 (Armonk, NY: IBM Corp).
Results
RCT characteristics
Of the 36 eligible RCTs identified (Additional file 2:
Appendix 2), 33 had secondary PRO endpoints, 1 had
a co-primary PRO endpoint, 1 had a tertiary PRO
endpoint and for 1 the PRO endpoint status was un-
clear (Table 1). Ten RCTs (28%) reported PRO results
in a separate publication. Just over half (n = 19, 53%)
reported a statistically significant difference between
treatment groups in at least one PRO scale, 14 (39%)
reported no PRO differences, and it was unclear whether
there were any PRO differences in the remaining 3 RCTs
(12%) as they did not report PRO results.
Completeness of PRO reporting
Total CONSORT-PRO scores (n = 36) ranged from 0 to
13.5/14, with a mean of 6.7 (48%). Most (n = 33, 92%)
reported some PRO results. Of the 3 (12%) RCTs that
did not report any PRO results, 2 stated that these
would be reported subsequently (CONSORT-PRO total
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scores of 0/14 and 1/14 respectively). The other did not
analyse the PRO data due to poor compliance, and did
not address any other recommended CONSORT-PRO
criteria, scoring 0/14. Another low-scoring publication
(scoring 1/14) simply reported that there were no
differences in global QOL at any time point, but did not
report the time points assessed, analysis methods, or re-
sults for other questionnaire domains. The majority of
RCTs addressed some CONSORT-PRO items: 27 (75%)
RCTs reported results of pre-specified PRO endpoints or
all domains of the PRO questionnaire used, 25 (69%)
interpreted PROs in the context of clinical endpoints, 19
(53%) provided the number of participants included in
each PRO analysis, and 23 (64%) cited evidence of the
validity of the PRO questionnaire used. However, other
items were reported poorly; most concerning was the
limited number of RCTs reporting baseline PROs
(n = 13, 36%), or reporting approaches for dealing with
missing PRO data (n = 14, 39%) (Fig. 2).
There was no apparent relationship between the year of
publication and CONSORT-PRO score (Additional file 3:
Appendix 3a), or CONSORT-PRO score and the PRO
protocol checklist total score (Fig. 3); however the 2 RCTs
with CONSORT-PRO scores of 0/14 also had PRO proto-
col scores <20%. There was no apparent difference in
CONSORT-PRO scores between RCTs with a significant
difference in the primary RCT endpoint, compared to
RCTs with no primary significant differences, or in RCTs
reporting a significant difference in the PRO endpoint
(n = 19) compared to RCTs reporting no significant PRO
difference (Additional file 3: Appendix 3b).
Reporting of PRO compliance
Information regarding PRO compliance reported ‘ad-
equately’ by 10 (28%) RCTs, and ‘incompletely’ by 16
(44%) RCTs. The remaining10 (25%) RCTs did not report
PRO compliance. Eight of 10 RCTs with adequately
reported compliance information addressed >11/14 (79%
or higher) CONSORT-PRO items, whilst the remaining 2
scored 3.5 and 4/14. Six (17%) RCTs reported a definition
of compliance, all of which were consistent with our defin-
ition and all bar one reported compliance ‘adequately’.
Nineteen (53%) RCTs reported the number of baseline ques-
tionnaires submitted, and all but 1 of these reported the num-
ber submitted for the principal analysis time-point. Six (17%)
RCTs reported use of a form to collect reasons for missing
PRO data, however, of these, only 3 reported ‘adequate’ compli-
ance information while 3 reported ‘incomplete’ information.
Dot plots showed a wide range in the distribution of PRO
protocol checklist scores for RCTs that reported any compli-
ance information compared to RCTs reporting none
(Additional file 3: Appendix 3c), however CONSORT-PRO
scores were higher for RCTs that reported any compliance in-
formation (t = 7.56, p < .001; Additional file 3: Appendix 3d).
Table 1 Characteristics of the 36 ovarian cancer RCTs
Characteristic No. of RCTs (%)
Publication in which
PRO results published
Main RCT publication 18 (50)
Dedicated publication 10 (28)
PROs not published 3 (8)
Year of main RCT
publication
2000–2009 15 (42)
2010–2016 21 (58)
Year of dedicated
PRO publication
2000–2009 4 (11)
2010–2016 6 (17)
No dedicated
QOL publication
26 (72)
PRO endpoint status Co-primary 1 (3)
Secondary 33 (96)
Tertiary 1 (3)
Unclear 1 (3)
PRO measures used EORTC QLQ-C30 a 24 (67)
EORTC QLQ-OV28 b 12 (33)
FACT-O c 11 (13)
Other FACIT d measures 4 (11)
EQ-5D e 4 (12)
Other 3 (8)
Sig. difference in primary
RCT endpoint
Yes f 15 (42)
No 21 (81)
Sig. difference in any
PRO scale reported
Yes f 19 (53)
No 14 (39)
Unclear, as no PRO
results reported
3 (8)
Intervention Chemotherapy 28 (78)
Targeted therapy 7 (19)
Surgery 2 (6)
Primary endpoint Progression-free
survival (PFS)
21 (58)
Overall survival 5 (14)
Survival (other) 3 (8)
All-cause mortality 2 (6)
Time to progression 2 (6)
PFS and QOL (co-primary) 1 (3)
Sponsors Clinical Trials Group 25 (69)
Commercial/
pharmaceutical
7 (19)
Co-sponsored: Trials
group and commercial
4 (11)
a European Organisation for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire-Core 30 (QLQ-C30)
b ovarian cancer module (QLQ-OV28), which is used with the QLQ-C30
c Functional Assessment of Cancer Therapy–Ovarian Cancer Module (FACT-O)
d Functional Assessment of Cancer Therapy (FACIT)
e the EuroQOL-5 dimensions (EQ-5D)
f Includes 1 RCT with co-primary PRO endpoint
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PRO compliance rates
Of the 10 RCTs that adequately reported PRO compli-
ance, compliance rates ranged from 59 to 83%. We were
able to examine the trial protocols of 6 of the 10 RCTs
which reported complete compliance information, and
those with higher PRO compliance rates at the primary
PRO analysis timepoint had higher PRO protocol check-
list scores (Fig. 4). However, there was no apparent rela-
tionship between compliance rates and CONSORT-PRO
scores (Fig. 5) among the 10 RCTs with ‘adequate’ com-
pliance information.
For 16 RCTs with incomplete compliance reporting, it
was not possible to determine their exact compliance
rates, because it was unclear how many observations
were included in the analysis or how many of the
missing assessments were due to participant death or
withdrawal (unavoidable/informative) as opposed to
avoidable reasons. However all these RCTs reported
increasing rates of missing PRO data overtime, as is
typical in cancer RCTs [26].
One RCT analysed PRO data only from 1 country
(representing less than a quarter of overall accrual), due to
poor compliance in other countries, though comparisons
of the analysed compared to accrued sample were clearly
presented and the paper reported compliance ‘adequately’.
Discussion
This study reviewed the relationship between the
completeness of PRO content of ovarian cancer RCT
protocols and corresponding publications and PRO
compliance rates. There was a large range in
CONSORT-PRO scores, much the same as we observed
a large variation in corresponding PRO protocol check-
list scores previously [25]. On average, RCTs reported
Fig. 2 Adherence of 36 ovarian cancer RCTs to CONSORT-PRO items. Legend: *Dark grey shading indicates the abstract identified the PRO as a
primary or secondary endpoint, light grey shading indicates the PRO was mentioned in the abstract but endpoint status was unclear. ^Awarded
if PRO domains were stated in PRO aims, objectives or hypotheses. CONSORT-PRO items P2b, P6, 13a, 17a and P20/21 contain multiple recom-
mendations and were divided into sub-items for scoring (See Additional file 1: Appendix 1b)
Fig. 3 Scatterplot of total CONSORT-PRO score and total PRO Proto-
col Checklist scores of 26 ovarian cancer RCTs. Legend: PRO results
were not published for the 3 RCTs marked with *. The protocols of
10 additional RCTs included in this study were not available for ana-
lysis and are excluded from this plot
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less than half the recommended CONSORT-PRO items.
The reporting of compliance was particularly poor, with
only 10 RCTs (28%) reporting this information
adequately. The 3 with the lowest PRO compliance rates
had lowest PRO protocol checklist scores, providing
some support for one of our motivating hypotheses -
that comprehensive consideration of PROs in the proto-
col will have beneficial effects on subsequent PRO data
collection. This highlights the need to address PRO
compliance strategies and provide clear PRO data collec-
tion guidance in the trial protocol and represents a po-
tential strategy to reduce the risk of missing PRO data in
future trials. Compliance rates were poor overall. The
highest reported compliance rate was 83%; therefore the
17% of participants with missing data at the principal
analysis time-point could have been avoided, possibly
through implementation of PRO quality assurance pro-
cesses [16]. The worst compliance rate reported was
59%, therefore a concerning 41% of participants in that
study had avoidably missing data.
Because survival time is short in advanced ovarian can-
cer [27, 28], trial participants may progress, stop protocol
treatment, withdraw from or die during trial follow-up.
Additionally, severe chemotherapy toxicity may result in
participants feeling too unwell to complete PROs. All of
these issues are likely to lead to missing data from partici-
pants who have poorer PROs and HRQOL outcomes; “in-
formative” missing PRO data. Indeed, women enrolled in
the Australian Ovarian Cancer Study demonstrated sharp
declines in QOL preceding drop out and those who
dropped out early had poorer QOL at baseline, suggesting
an informative missing PRO data pattern [29]. We found
that 16 (44%) RCTs reported incomplete compliance in-
formation, meaning that despite the authors’ attempts to
report information about missing data, it was unclear
whether missing data was informative of poor health sta-
tus or avoidable. In all PRO studies, particularly when
compliance is poor, authors need to describe the reasons
for missing PRO data and the analysis sample’s represen-
tativeness to the target population in line with
CONSORT-PRO, to enable the reader to understand the
external validity and generalizability of the results [16, 20].
Failing to report the number of participants from whom
PROs were expected, and the reasons for missing PRO
data, makes it difficult for readers to determine whether
missing data are related to poor health status or not, and
therefore to assess the generalizability and credibility of
the trial findings and conclusions [29].
Statisticians also need to know the reasons for missing
PRO data so they may handle it appropriately in analyses
[26]. Thus it is important that reasons for missing PRO
data are collected in real-time by site staff, so this
requirement should be stated in the trial protocol. Yet only
6 (17%) RCTs in this cohort collected this information.
Only 2 of these 6 RCTs went on to report compliance in-
formation adequately (PRO compliance rates of 74 and
83% respectively at their primary analysis time-points). The
remaining 4 RCTs reported compliance incompletely; com-
pletion rates among these 4 RCTs ranged from 40 to 51%,
Fig. 5 Scatterplot of PRO compliance percentage at the primary
PRO analysis timepoint and CONSORT-PRO reporting score. Legend:
PRO compliance rate was clearly reported for 10 of the 36 RCTs in-
cluded in this study. The mean PRO CONSORT-PRO score for these
10 RCTs was 10.5/14, range: 4–13/14. Compliance data was not re-
ported adequately in the remaining 26 RCT publications, therefore
these have been excluded here. The mean CONSORT-PRO score for
these 26 RCTs was 5.3/14, range 0–13.5/14
Fig. 4 Scatterplot of PRO compliance percentage at the primary
PRO analysis timepoint and PRO protocol checklist total score.
Legend: PRO compliance rate was clearly reported for 6 of the 26
RCTs for which trial protocols were obtained. The mean PRO
protocol score for these 6 RCTs was 34.9%, range: 14.8–65.5%. Of the
remaining 20 RCTs with available PRO protocol scores, compliance
data was not reported adequately in the publication. The mean PRO
protocol score for these 20 RCTs was 26.4%, range 8.3–50%. PRO
protocol checklist scores for all 26 RCT protocols are described in
detail in [25]
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however the extent of informatively (unavoidably) missing
data was unclear.
We found that 2 RCTs failed to report PRO data due to
poor compliance. This represents a waste of research ef-
fort as unpublished PRO data cannot possibly be used to
improve knowledge or inform clinical practice [15, 30].
Failing to publish PRO data due to poor compliance de-
values the contributions and data of compliant partici-
pants and centres. Some believe that if PRO compliance
falls below a certain threshold, then the data are too un-
representative to be of use. Whilst this may be true if stat-
istical power is significantly reduced or if remaining
participants are grossly unrepresentative of the recruited
sample, we argue that transparent reporting of rates and
reasons for missing data can inform robust interpretation,
if the authors discuss generalisability concerns informed
by clinical data collected on these participants [16, 31].
There is no substitute for high PRO completion rates, and
trial staff should routinely be reminded of this as a quality
assurance measure. However, poor compliance should not
always be viewed as a barrier to publication, particularly
where missing data was unavoidable and/or informative of
poor participant health; the PROs of the compliant partici-
pants may still be of interest and value. In the context of
ovarian cancer RCTs, the PRO-compliant subgroup is
likely to over-represent participants who have stable dis-
ease or are responding well to treatment–this is certainly
a subgroup of interest, because the QOL of the surviving
participants who do well on treatment matters. The
results of these participants should be reported as an
important sub-group of the recruited sample, not as a
representative sub-group of the recruited sample, as the
latter would present an overly optimistic picture of the
effects of the trial treatments (bias). Not reporting any
PRO data at all due to poor compliance represents a
failure to extract the important evidence in the available
data (research waste).
We did not see a relationship overall between protocol
content and CONSORT-PRO reporting scores in this
sample. Encouragingly this finding suggests that PRO
endpoints may reported in line with CONSORT-PRO
guidance, even if the trial protocol did not comprehen-
sively address PROs. However, further research is needed
as we found that the 2 RCTs that did not report any de-
tails on their PRO studies (i.e. CONSORT-PRO scores
of 0) addressed less than 20% of recommended PRO-
specific protocol items. Non-reporting of PRO results is
undoubtedly emerging as a problem in this field. Schan-
delmaier and colleagues found only 20% of 173 oncology
RCTs with PRO endpoints listed in the protocol subse-
quently went on to publish the PRO data [32]- again
demonstrating research waste [33].
Some CONSORT-PRO items were reported by most
RCTs, for example 75% reported results by PRO domain
and 69% of publications discussed PRO results in the
context clinical endpoints, yet the limited number of
RCTs that reported baseline PROs (36%) and approaches
for missing data (42%) is concerning. Failing to report
this information, and incomplete reporting generally,
can lead to biased interpretation or make it difficult to
assess generalisability of results, which in turn may limit
the potential for PROs to impact policy decisions and
patient care. It must be noted that all of the RCTs
included in our review were designed without the benefit
of the yet-to-be-finalised SPIRIT-PRO checklist, and many
(69%) were published before the release of CONSORT-
PRO guidance in 2013. The deficiencies summarised in
this paper underscore the value of those checklists. We
hope that by identifying these issues, future investigators
will take necessary steps towards improving the quality
and dissemination of PRO data collected in RCTs.
Historically, PROs have had a limited role in oncology
labelling claims. The earliest FDA drug approval for on-
cology was in 1995 [34], and by 2006 only a small pro-
portion of oncology drug approvals had included PRO
evidence [35]. A more recent critique of ovarian cancer
trials reveals that PROs are often omitted or not ana-
lysed despite their obvious relevance in this context [13].
Oncology societies and policy makers are now formally
recognising the value of PROs. QOL is incorporated into the
scoring of the ESMO Magnitude of Clinical Benefit Scale
(MCBS) for the management of solid cancers without cura-
tive intent, whereby the maximum MCBS score can only be
achieved if the therapy “demonstrates improved QOL or de-
layed deterioration in QOL using a validated scale” as well as
superior survival (Cherny, et al., 2015, p1550, [5]). Similarly,
ASCO incorporates QOL into the recently-developed Net
Health Benefit Framework for advanced disease, which aims
to facilitate physician and patient access to information for
shared treatment decision-making according to individual
patient preferences and circumstances [4]. These initiatives
represent real potential for PROs to impact care. PRO
researchers must seize this opportunity not only to include
PROs when they are relevant, but to improve PRO re-
search practice and, by consequence, the quality and impact
of PRO evidence. Therefore PRO studies must be designed,
conducted and reported to the highest standards to be of
most benefit to patient care. Our findings suggest that: 1) ad-
herence to the forthcoming SPIRIT-PRO Extension and
CONSORT-PRO Extension for the development of protocols
and publications respectively, and 2) prospectively collecting
reasons for missing data and reporting these reasons in the
publication, can assist researchers to ensure that high-quality
PRO evidence is available and utilised in clinical practice.
Strengths
This study of all ovarian cancer RCTs published over a
16 year period describes key PRO methodological
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shortfalls and their potential impact in a clinical sub-
group for which PROs are outcomes of high importance.
Two authors independently scored protocols and
publications, and extracted data. Checklists used to
assess protocols and publications were based on current
evidence for international best practice in PRO research.
We were able to obtain the majority of RCT protocols,
even though many of these were not publically available
due to their age. RCT authors did not have access to the
PRO protocol checklist used, therefore it is unlikely that
protocols were augmented prior to our analysis. Specific
methodological issues addressed in this review, such as
handling and reporting of missing PRO data, are particu-
larly meaningful to ovarian cancer trials and trials of
other disease groups.
Limitations
Although we did not observe a clear relationship be-
tween overall reporting completeness and PRO protocol
checklist score in ovarian cancer RCTs, this does not
rule out such a relationship in oncology RCTs generally.
We could not assess whether trial staff adhered to proto-
col instructions, which may have impacted PRO compli-
ance rates. Our analysis of the relationship between PRO
compliance rates with protocol and reporting scores
should be interpreted with caution, as this analysis was
limited by the small number of trials adequately report-
ing PRO compliance; however this limitation independ-
ently represents an important finding (that compliance
is poorly reported) relevant to our aims.
Next steps
Further work on the impact of PRO protocol content on
the quality of data and reporting is needed in other clinical
sub-groups for which PROs are of particular importance,
and in oncology generally. A similar analysis in a mixed
oncology cohort is ongoing as part of the UK Macmillan
Cancer Support EPiC study [36]. Relationships between
protocols and reporting may emerge in this heterogeneous
oncology RCT sample, with a broader variety of PRO and
other RCT endpoints, and investigators.
Conclusions
This study provides preliminary evidence that a trial
protocol with more complete details on the PRO endpoint
may reduce the risk of avoidable missing PRO data. Poor
compliance led to non-reporting of PROs for 2 RCTs,
meaning that efforts invested into PRO data collection for
these RCTs was wasted as the PRO data cannot possibly
impact patient care. It also provides evidence that the
reporting of PROs requires improvement, particularly
reporting of the rates, reasons and impact of missing PRO
data. Given that rates of avoidable and informative missing
PRO data were quite high in this sample, clear reporting is
crucial and should include a transparent discussion of
generalisability concerns in light of avoidable and inform-
ative missing data. Investigators should refer to the forth-
coming SPIRIT-PRO Extension [23] to develop PRO
aspects of trial protocols with clear strategies to minimise
the missing data, as well as the CONSORT-PRO guidance
for reporting [20]. Such efforts will ensure high-quality
PRO findings are accurately interpreted and can meaning-
fully impact patient care.
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Additional file 2: Appendix 2. List of Included RCTs. (DOCX 21 kb)
Additional file 3: Appendix 3. Supplementary plots. (DOCX 135 kb)
Acknowledgements
We are grateful to the Gynaecologic Cancer Inter-Group (GCIG) Symptom Benefit
Working Group (SBWG) ImPROVeD Contributor’s Group leaders Professors Michael
Friedlander, Felix Hilpert and Florence Joly, and to RCT investigators for providing
access to trial protocols; specifically (in alphabetical order) DK Armstrong, J Berek,
N Colombo, M Bookman, M Brady, J Bryce, A du Bois, G Elser, A Harkin, S Kaye, J
Ledermann, K Lindemann, B Monk, T Perren, M Piccart, S Pignata, J Pfisterer, E
Pujade-Lauraine, N Reed, G Rustin, J Sehouli, P Vasey, I Vergote. We also
acknowledge F Roncolado and A Long for their assistance identifying
eligible trials; and the International Society for Quality of Life Research
Best Practices for PROs Protocol Checklist Taskforce for their contribution to developing
the PRO Protocol Checklist. RMB is supported by the Cancer Institute NSW via Sydney
Catalyst. MK is supported by the Australian Government via Cancer Australia.
Funding
There are no funders to report for this submission.
Authors’ contributions
RMB: concept, obtained materials for analysis, data extraction, analysis, wrote
and edited manuscript. MF: concept, obtained materials for analysis, edited
manuscript. MC: concept, edited manuscript. MS: concept, edited manuscript.
DK: edited manuscript. PSK: data extraction. MK: concept, edited manuscript.
All authors read and approved the final manuscript.
Ethics approval and consent to participate
This article is an analysis of published RCT publications and their protocols. It did not
involve human participants, therefore human ethics approval was not required.
Competing interests
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/
coi_disclosure.pdf and declare: no support from any organisation for the submitted
work. Outside the submitted work: MF has received funding from ASTRA ZENECA
and PFIZER. MC received grants from Macmillan Cancer Support, personal fees from
Ferring Pharma. MC and MK co-chair and RMB and DC are members of the
International Society for Quality of Life Research Best Practices for PROs in Trials
Taskforce and are involved in the development of the SPIRIT-PRO extension. MC first
author of the CONSORT-PRO Extension and leading the development of the SPIRIT--
PRO extension. None of these relationships or activities have influenced the submitted
work.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Central Clinical School, Sydney Medical School, University of Sydney,
Sydney, NSW, Australia. 2Psycho-oncology Co-operative Research Group,
School of Psychology, University of Sydney, Level 6 North, Chris O’Brien
Mercieca-Bebber et al. Journal of Patient-Reported Outcomes  (2017) 1:5 Page 9 of 10
Lifehouse C39Z, Sydney, NSW, Australia. 3NHMRC Clinical Trials Centre,
University of Sydney, Camperdown, NSW, Australia. 4Australian New Zealand
Gynecological Oncology Group (ANZGOG), Camperdown, NSW, Australia.
5Centre for Patient-Reported Outcomes Research, University of Birmingham,
Edgbaston, Birmingham, UK.
Received: 12 April 2017 Accepted: 7 August 2017
References
1. Au, H. J., Ringash, J., Brundage, M., Palmer, M., Richardson, H., & Meyer, R. M.
(2010). Added value of health-related quality of life measurement in cancer
clinical trials: The experience of the NCIC CTG. Expert Review of
Pharmacoeconomics & Outcomes Research, 10(2), 119–128.
2. Food and Drug Administration. Guidance for Industry: Patient-Reported
Outcome Measures: Use in Medical Product Development to Support
Labelling Claims2009. Available from: http://www.fda.gov/downloads/
Drugs/Guidances/UCM193282.pdf. Accessed 10 Oct 2016.
3. European Medicines Agency. (2016). Appendix 2 to the guideline on the
evaluation of anticancer medicinal products in man: The use of patient-
reported outcome (PRO) measures in oncology studies. London, UK. http://
www.ema.europa.eu/docs/en_GB/document_library/Other/2016/04/
WC500205159.pdf. Accessed 10 Oct 2016.
4. Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA,
et al. (2016). Updating the American Society of Clinical Oncology Value
Framework: Revisions and Reflections in Response to Comments Received.
Journal of Clinical Oncology, 34(24), 2925–2934. doi:10.1200/JCO.2016.68.2518
5. Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., et al.
(2015). A standardised, generic, validated approach to stratify the
magnitude of clinical benefit that can be anticipated from anti-cancer
therapies: The European Society for Medical Oncology magnitude of clinical
benefit scale (ESMO-MCBS). Annals of Oncology, 26(8), 1547–1573.
6. Hess, L. M., & Stehman, F. B. (2012). State of the science in ovarian cancer
quality of life research: A systematic review. International Journal of
Gynecological Cancer, 22(7), 1273–1280.
7. Friedlander, M. L., & King, M. T. (2013). Patient-reported outcomes in ovarian
cancer clinical trials. Annals of Oncology, 24(suppl 10), x64–xx8.
8. Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N.,
Sessa, C., et al. (2013). Newly diagnosed and relapsed epithelial ovarian
carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Annals of Oncology, 24(suppl 6), vi24–vi32.
9. du Bois, A., Quinn, M., Thigpen, T., Vermorken, J., Avall-Lundqvist, E.,
Bookman, M., et al. (2004, 2005, 16). Consensus statements on the
management of ovarian cancer: Final document of the 3rd international
gynecologic cancer intergroup ovarian cancer consensus conference (GCIG
OCCC 2004). Annals of Oncology, (Suppl 8), viii7–viii12.
10. Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M.,
et al. (2011). Clinical trials in recurrent ovarian cancer. International Journal of
Gynecological Cancer, 21(4), 771–775. doi:10.1097/IGC.0b013e31821bb8aa
11. Stuart, G. C., Kitchener, H., Bacon, M., du Bois, A., Friedlander, M.,
Ledermann, J., et al. (2011). 2010 gynecologic cancer inter group (GCIG)
consensus statement on clinical trials in ovarian cancer: Report from the
fourth ovarian cancer consensus conference. International Journal of
Gynecological Cancer, 21(4), 750–755. doi:10.1097/IGC.0b013e31821b2568
12. Food and Drug Administration. (2006). Ovarian Cancer Endpoints
Workshop April 26 2006 meeting summary. Available from: https://
www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm120657.pdf.
Accessed 9 Aug 2016.
13. Friedlander, M., Mercieca-Bebber, R., & King, M. (2016). Patient reported
outcomes in ovarian cancer clinical trials-lost opportunities and lessons
learned. Annals of Oncology, 27(S1), i66–i71.
14. Kyte, D., Ives, J., Draper, H., Keeley, T., & Calvert, M. (2013). Inconsistencies in
quality of life data collection in clinical trials: A potential source of bias?
Interviews with research nurses and Trialists. Plos One, 8(10), e76625.
15. Ioannidis, J. P. A., Greenland, S., Hlatky, M. A., Khoury, M. J., Macleod, M. R.,
Moher, D., et al. (2014). Increasing value and reducing waste in research
design, conduct, and analysis. The Lancet, 383(9912), 166–175.
16. Mercieca-Bebber, R., Palmer, M. J, Brundage, M., Calvert, M., Stockler, M. R.,
King, M. T., (2016). Design, implementation and reporting strategies to
reduce the instance and impact of missing patient-reported outcome (PRO)
data: a systematic review. BMJ Open, 6(6). http://dx.doi.org/10.1136/
bmjopen-2015-010938
17. Fairclough, D. L., Peterson, H. F., & Chang, V. (1998). Why are missing quality
of life data a problem in clinical trials of cancer therapy? Statistics in
Medicine, 17(5–7), 667–677.
18. Bernhard, J., Cella DF, Coates, A. S., Fallowfield, L., Ganz, P. A, Moinpour, C. M,
et al. (1998). Missing quality of life data in cancer clinical trials: Serious
problems and challenges. Statistics in Medicine, 17(5–7), 517–532.
19. Osoba, D., Bezjak, A., Brundage, M., Zee, B., Tu, D., & Pater, J. (2005). Analysis
and interpretation of health-related quality-of-life data from clinical trials:
Basic approach of the National Cancer Institute of Canada clinical trials
group. European Journal of Cancer, 41(2), 280–287.
20. Calvert, M., Blazeby, J., Altman, D. G., et al. (2013). Reporting of patient-
reported outcomes in randomized trials: The CONSORT-PRO extension.
JAMA, 309(8), 814–822.
21. Efficace, F., Fayers, P., Pusic, A., Cemal, Y., Yanagawa, J., Jacobs, M., et al. (2015).
Quality of patient-reported outcome reporting across cancer randomized
controlled trials according to the CONSORT patient-reported outcome
extension: A pooled analysis of 557 trials. Cancer, 121(18), 3335–3342.
22. Bylicki, O., Gan, H. K., Joly, F., Maillet, D., You, B., & Péron, J. (2014). Poor
patient-reported outcomes reporting according to CONSORT guidelines in
randomized clinical trials evaluating systemic cancer therapy. Annals of
Oncology, 26(1), 231–237.
23. Calvert, M., Kyte, D., von Hildebrand, M., King, M., & Moher, D. (2015). Putting
patients at the heart of health-care research. The Lancet, 385(9973), 1073–1074.
24. Calvert, M., Kyte, D., Duffy, H., Gheorghe, A., Mercieca-Bebber, R., Ives, J., et al.
(2014). Patient reported outcome (PRO) assessment in clinical trials: A
systematic review of guidance for trial protocol writers. Plos One, 9(10),
e110216.
25. Mercieca-Bebber, R., Friedlander, M., Kok, P.-S., Calvert, M., Kyte, D., Stockler, M.,
et al. (2016). The patient-reported outcome content of international ovarian
cancer randomised controlled trial protocols. Quality of Life Research, 25(10),
2457–2465. doi:10.1007/s11136-016-1339-x
26. Fairclough, D. L. (2004). Patient reported outcomes as endpoints in medical
research. Statistical Methods in Medical Research, 13(2), 115–138 Epub 2004/04/08.
27. Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: a
Cancer Journal for Clinicians, 66(1), 7–30 Epub 2016/01/09.
28. Hanker, L. C., Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E.,
et al. (2012). The impact of second to sixth line therapy on survival of relapsed
ovarian cancer after primary taxane/platinum-based therapy. Annals of
Oncology, 23(10), 2605–2612 Epub 012 Aug 21.
29. Mercieca-Bebber RL, Price M, Bell M, King MT, Webb P, PN Butow, et al.
Ovarian cancer study dropouts had worse health-related quality of life and
psychosocial symptoms at baseline and overtime. Asia-Pacific Journal of
Clinical Oncology, doi:10.1111/ajco.12580
30. Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., et al.
(2014). Reducing waste from incomplete or unusable reports of biomedical
research. The Lancet, 383(9913), 267–276.
31. Bell, M. L., & Fairclough, D. L. (2014). Practical and statistical issues in missing
data for longitudinal patient-reported outcomes. Statistical Methods in
Medical Research, 23(5), 440–459.
32. Schandelmaier, S., Conen, K., von Elm, E., You, J. J., Blumle, A., Tomonaga, Y.,
et al. (2015). Planning and reporting of quality-of-life outcomes in cancer
trials. Annals of Oncology, 26(9), 1966–1973. Epub 2015 Jun 30. doi:10.1093/
annonc/mdv283
33. Chalmers, I., & Glasziou, P. (2009). Avoidable waste in the production and
reporting of research evidence. The Lancet, 374(9683), 86–89.
34. Rock, E. P., Kennedy, D. L., Furness, M. H., Pierce, W. F., Pazdur, R., & Burke, L. B.
(2007). Patient-reported outcomes supporting anticancer product approvals.
Journal of Clinical Oncology, 25(32), 5094–5099.
35. Gondek, K., Sagnier, P.-P., Gilchrist, K., & Woolley, J. M. (2007). Current status
of patient-reported outcomes in industry-sponsored oncology clinical trials
and product labels. Journal of Clinical Oncology, 25(32), 5087–5093.
36. Ahmed, K., Kyte, D., Keeley, T., Efficace, F., Armes, J., Brown, J. M., et al. (2016).
A systematic evaluation of patient-reported outcome (PRO) protocol
content and reporting in UK cancer clinical trials: The EPiC study protocol.
BMJ Open, 6.
Mercieca-Bebber et al. Journal of Patient-Reported Outcomes  (2017) 1:5 Page 10 of 10
